Clinical Trials on Refractory Hematologic Cancer

Total 67252 results

Institut Paoli-Calmettes
Hospital Clínico Universitario de Valencia

Unknown

TORQUETENOVIRUS IN CAR-T THERAPY: PREDICTION OF THE CRS (TTV-CART)

Hematologic Cancer
University of Maryland, Baltimore

Active, not recruiting

Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

Relapsed or Refractory Acute Myeloid Leukemia

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Acute Leukemia | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Acute Lymphoblastic Leukemia | Systemic Mastocytosis | Recurrent Hematologic Malignancy | Hairy Cell Leukemia | Chronic... and other conditions
Yazeed Sawalha

Withdrawn

Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular Lymphoma | Refractory Grade 1 Follicular... and other conditions
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Adult Acute Myeloid Leukemia in Remission | Adult Acute Lymphoblastic Leukemia in Remission | Refractory Anemia With Excess Blasts | Refractory... and other conditions

United States
Fudan University

Completed

Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study

Metastatic Colorectal Cancer | Colorectal Cancer | Refractory Colorectal Cancer

China
Beijing GoBroad Hospital

Recruiting

Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia

Refractory/Relapsed Acute Myeloid Leukaemia

China
Gilead Sciences

No longer available

US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia
Novartis Pharmaceuticals

Terminated

Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone

Hormone Refractory Prostate Cancer

United States
Celgene

Completed

ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer

Hormone Refractory Prostate Cancer

United States
Queen's Medical Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Completed

Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer

Hormone Refractory Prostate Cancer

United States
Spanish Oncology Genito-Urinary Group

Completed

Study of Weekly Cabazitaxel for Advanced Prostate Cancer

Hormone Refractory Prostate Cancer

Spain
Daniel George, MD
Novartis Pharmaceuticals

Completed

RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer

Hormone Refractory Prostate Cancer

United States
Dendreon

Completed

Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer

Hormone-Refractory Prostate Cancer
Medical University of Vienna

Unknown

Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer

Hormone Refractory Prostate Cancer

Austria
Sheba Medical Center

Unknown

Efficacy of FWGE in Combination With Hormone Therapy for the Treatment of Hormone-Refractory Prostate Cancer Patients

Hormone Refractory Prostate Cancer

Israel
Antisoma Research

Completed

Phase I Safety Study of DMXAA in Refractory Tumors (DART)

Refractory Tumors
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors (PIONEER)

Solid Tumor, Adult | Solid Tumor, Childhood | Hematologic Cancer

France
The First Affiliated Hospital of Soochow University

Recruiting

Correlation Between Gut Microbiota and Clinical Response to CAR-T Treatment for Hematological Malignancies

Hematological Malignancies | Chimeric Antigen Receptor T-cell Therapy

China
M.D. Anderson Cancer Center
Roche Pharma AG

Completed

Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients

Hematological Malignancies

United States
Dr. Avichai Shimoni MD
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Withdrawn

Allogenic Transplantation of Ex-vivo Expanded Cord Blood (CB)

Stem Cell Transplantation | Hematological Malignancies | Umbilical Cord Blood
Hangzhou Sumgen Biotech Co., Ltd.

Recruiting

SG2501 Safety Study in Subjects With Relapsed or Refractory Hematological Malignancies and Lymphoma.

Lymphoma | Hematological Malignancy

United States
Assistance Publique - Hôpitaux de Paris

Completed

Immunoregulatory T Lymphocytes Subtypes and Haematopoietic Stem Cell Transplantation (HSCT) (REG-Allo)

Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies

France
Zealand University Hospital

Unknown

Patient-Reported Outcomes Integrated in the Follow-up of Patients With Hematological Cancer

Hematological Cancer

Denmark
Hutchmed

Recruiting

A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH

Isocitrate Dehydrogenase Gene Mutation

Spain, United States
Effector Therapeutics

Terminated

A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies

Lymphoma

United States
Samsung Medical Center

Completed

Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors

Refractory Solid Tumors

Korea, Republic of
Samsung Medical Center

Completed

Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors

Refractory Solid Tumors

Korea, Republic of
First Affiliated Hospital of Zhejiang University

Unknown

Effectivity and Safety of Irreversible Electroporation for Refractory Neoplasms in Liver and Pancreas

Refractory Neoplasms

China
SCRI Development Innovations, LLC
Bayer

Completed

Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors

Refractory Malignancy

United States
Sydney Children's Hospitals Network
German Cancer Research Center; Australian & New Zealand Children's Haematology... and other collaborators

Active, not recruiting

PRecISion Medicine for Children With Cancer (PRISM)

Childhood Cancer | Relapsed Cancer | Refractory Cancer | Childhood Leukemia | Childhood Solid Tumor | Childhood Brain Tumor

Australia
Acrotech Biopharma Inc.
Axis Clinicals Limited

Completed

Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies

Refractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell Lymphoma

United States
King Abdullah International Medical Research Center

Completed

Daily Ginger Drinking and Platelet Function

Hematological Diseases | Platelets Dysfunction

Saudi Arabia
University of Magdeburg

Completed

Capillary and Venous Blood Count Parameters

Healthy Volunteers | Hematological Diseases
Case Comprehensive Cancer Center

Withdrawn

Intervention for Caregivers of Patients Undergoing HSCT or CAR T-cell Therapy

Blood Cancer
iCell Gene Therapeutics
iCar Bio Therapeutics

Recruiting

CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma

Relapsed/Refractory, High Risk Hematologic Malignancies | T-ALL/Lymphoma

China
University Hospital Heidelberg
University of Cologne; University Hospital Freiburg; University Hospital Dresden

Terminated

Pre-Exercise for Allogeneic Stem Cell Transplant Patients (PRESENT-P)

Cancer, Hematological

Germany
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Plasma Cell Myeloma

United States
Nerviano Medical Sciences

Completed

PHA-739358 for Treatment of Hormone Refractory Prostate Cancer

Metastatic Hormone Refractory Prostate Cancer

Italy
Nottingham University Hospitals NHS Trust
Newcastle University; University of Kansas; Macmillan Cancer Support; Bishop Grosseteste...

Terminated

Nutrition Health Literacy of Cancer Patients and Their Support Networks. (NiiCproject)

Cancer | Oncologic Disorders | Nutrition Aspect of Cancer | Haematological Malignancy

United Kingdom
GenesisCare USA
Dendreon

Completed

A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T

Castrate Refractory Metastatic Prostate Cancer (mCRPC)

United States
University of Washington
Bristol-Myers Squibb

Active, not recruiting

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory Plasma Cell Myeloma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma and other conditions

United States
Immatics US, Inc.

Recruiting

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (ACTengine)

Cancer | Solid Tumor, Adult | Refractory Cancer | Recurrent Cancer

United States, Germany
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia (HAPLO-EMPTY)

Refractory Idiopathic Aplastic Anemia | Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation
Masonic Cancer Center, University of Minnesota

Recruiting

Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia

Myelodysplastic Syndromes | Leukemia | Previously Treated Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Childhood Acute Myeloid Leukemia in Remission | Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Myeloid Leukemia | Secondary Myelodysplastic Syndrome and other conditions

United States
M.D. Anderson Cancer Center
Kura Oncology, Inc.

Not yet recruiting

A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias

Refractory Acute Leukemia | Pediatric Relapsed

United States
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia

AML | Refractory | Relapsed

China
St. Justine's Hospital

Not yet recruiting

Fertility Preservation With Ovarian Tissue Freezing (PTO)

Cancer | Infertility | Ovarian Failure | Hematologic Disorder

Canada
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

Refractory Acute Lymphoblastic Leukemia | Philadelphia-Negative ALL | Philadelphia-Positive ALL | Refractory Acute Lymphoblastic Leukemia (ALL) | Relapsed ALL, Adult | Refractory Acute Lymphoid Leukemia in Relapse

United States

Clinical Trials on Refractory Hematologic Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations